Imaging examination is an indispensable and important diagnostic method for prostate cancer. ⁶⁸Gallium labeled prostate-specific membrane antigen targeted positron emission tomography-computed tomography (⁶⁸Ga-PSMA PET-CT) is a new imaging technique that has been applied in clinic in recent years. Its popularization and application benefit from the excellent diagnostic efficacy, unique value in the diagnosis of primary and metastatic prostate cancer, clinical decision-making guidance, biochemical recurrence detection and prognosis evaluation, and the broad prospect in realizing the integration of diagnosis and treatment of tumor. Based on the complementary advantages of ⁶⁸Ga-PSMA PET-CT and magnetic resonance imaging (MRI), European Association of Urology guidelines have recommended ⁶⁸Ga-PSMA PET-CT for patients with biochemical recurrence after prostatectomy. With the accumulation of clinical experience and in-depth understanding of clinicians, ⁶⁸Ga-PSMA PET-CT will play a greater role in the diagnosis and clinical decision-making of prostate cancer.